Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study.

ABSTRACT:

Background

Radium-233 dichloride is an alpha emitter that specifically targets bone metastases in prostate cancer. Results of a previously reported phase III randomized trial showed survival benefit for radium-223 compared to best supportive care in castration-resistant prostate cancer (CRPC) with bone metastases. However, real-world data are also needed with wider inclusion criteria.

Methods

We report results of a retrospective multicenter study including all patients with metastatic CRPC treated with radium-223 in all five university hospitals in Finland since the introduction of the treatment. We identified 160 patients who had received radium-223 in Finland in 2014-2019.

Results

The median overall survival (OS) was 13.8 months (range 0.5-57 months), and the median

SUBMITTER: Hyvakka A 

PROVIDER: S-EPMC9972699 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature